Printer Friendly


BOFFINS at a Welsh university have made a breakthrough in their search for a cure for leukaemia.

The Cardiff University team have discovered that large amounts of a protein called NF-kB are linked to the growth of chronic lymphocytic leukaemia-the most common form of the disease in adults in the UK.

Patients with the most aggressive form of the disease also had the highest levels of NF-kB.

Dr Saman Hewamana, a Leukaemia Research clinical training fellow, has also been able to show that an experimental drug can block NF-k Baction, which results in the death of leukaemia cells.

The new drug also kills leukaemia cells taken from patients who are resistant to conventional chemotherapy and the drug does not appear to harm normal blood cells.

It could spare patients from the effects of conventional chemotherapy.

The drug will be tested for the first time in patients with the disease in trials in Cardiff in the near future.

Dr Chris Pepper, who is leading the research, said: "If these very promising results can be repeated in the clinical setting, it seems likely that drugs aimed at disabling NF-kB will become an important addition to the treatment options for this form of leukaemia."
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Wales On Sunday (Cardiff, Wales)
Date:Feb 10, 2008
Previous Article:Head's ban splits village.
Next Article:Furious battle casts shadow.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters